Jorge I Gamez-Nava Selected Research

Jorge I Gamez-Nava Research Topics

10	Rheumatoid Arthritis 01/2022 - 01/2009
3	Inflammation (Inflammations) 01/2021 - 01/2021
3	Ankylosing Spondylitis 06/2017 - 03/2002
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2019 - 08/2002
2	Pain (Aches) 10/2017 - 01/2009
2	Osteoporosis 02/2012 - 03/2009
1	Rheumatic Diseases (Rheumatism) 01/2021
1	Cachexia 01/2021
1	Hypertension (High Blood Pressure) 01/2019
1	Insulin Resistance 01/2019
1	Disease Progression 10/2017
1	Proteinuria 01/2017
1	Lupus Nephritis 01/2017
1	Diffuse Scleroderma (Progressive Systemic Sclerosis) 09/2015
1	Interstitial Lung Diseases (Interstitial Lung Disease) 09/2015
1	Dermatomyositis (Dermatopolymyositis) 04/2013
1	Joint Diseases (Joint Disease) 01/2009
1	Hyperhomocysteinemia 10/2008
1	Spondylarthropathies 08/2004

4	ametantrone (HAQ)IBA 10/2017 - 08/2004
4	Methotrexate (Mexate)FDA LinkGeneric 10/2017 - 08/2004
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2017 - 03/2002
4	LeptinIBA 06/2017 - 08/2002
3	CytokinesIBA 01/2021 - 03/2002
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2017
2	AdipokinesIBA 01/2021 - 06/2017
2	AdiponectinIBA 06/2017 - 01/2017
1	Leflunomide (Arava)FDA LinkGeneric 01/2022
1	MyostatinIBA 01/2021
1	Neuropeptide YIBA 01/2020
1	Triglycerides (Triacylglycerol)IBA 01/2019
1	CholesterolIBA 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 01/2019
1	LDL CholesterolIBA 01/2019
1	Uric Acid (Urate)IBA 01/2019
1	Triggering Receptor Expressed on Myeloid Cells-1IBA 10/2017
1	Antirheumatic Agents (DMARD)IBA 10/2017
1	Interleukin-6 (Interleukin 6)IBA 06/2017
1	Procollagen Type IIBA 09/2015
1	LipidsIBA 01/2014
1	Etanercept (Enbrel)FDA Link 01/2014
1	Mi-2 antibodiesIBA 04/2013
1	AutoantibodiesIBA 04/2013
1	Estrogens (Estrogen)FDA Link 02/2012
1	E-SelectinIBA 01/2009
1	SelectinsIBA 01/2009
1	Rheumatoid FactorIBA 01/2009
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 10/2008
1	Interleukin-10 (Interleukin 10)IBA 03/2002
1	Interleukin-1beta (Interleukin 1 beta)IBA 03/2002
1	cyclopropapyrroloindoleIBA 03/2002

1	Therapeutics 10/2017